DDInter576 DDInter1409
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Disulfiram {u} (Compound) treats {v} (Disease) alcohol dependence
alcohol dependence {u} (Disease) is treated by {v} (Compound) Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Disulfiram {u} (Compound) binds {v} (Gene) DBH
DBH {u} (Gene) is bound by {v} (Compound) Propylthiouracil
Propylthiouracil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Disulfiram {u} (Compound) upregulates {v} (Gene) FHL2
FHL2 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Disulfiram {u} (Compound) upregulates {v} (Gene) IL11
IL11 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Disulfiram {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Bupropion
Bupropion {u} may lead to a major life threatening interaction when taken with {v} Peginterferon beta-1a
Disulfiram {u} (Compound) upregulates {v} (Gene) MYC
MYC {u} (Gene) is downregulated by {v} (Compound) Bupropion
Bupropion {u} may lead to a major life threatening interaction when taken with {v} Peginterferon beta-1a
Disulfiram {u} (Compound) upregulates {v} (Gene) CXCL8
CXCL8 {u} (Gene) is bound by {v} (Compound) Ketoprofen
Ketoprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Disulfiram {u} (Compound) upregulates {v} (Gene) PAK1
PAK1 {u} (Gene) is upregulated by {v} (Compound) Tramadol
Tramadol {u} may lead to a major life threatening interaction when taken with {v} Peginterferon beta-1a
Disulfiram {u} (Compound) downregulates {v} (Gene) NR2F6
NR2F6 {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Disulfiram {u} (Compound) downregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Disulfiram (Compound) treats alcohol dependence (Disease) and alcohol dependence (Disease) is treated by Naltrexone (Compound) and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Disulfiram (Compound) binds DBH (Gene) and DBH (Gene) is bound by Propylthiouracil (Compound) and Propylthiouracil may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Disulfiram (Compound) upregulates FHL2 (Gene) and FHL2 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Disulfiram (Compound) upregulates IL11 (Gene) and IL11 (Gene) is downregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Disulfiram (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Bupropion (Compound) and Bupropion may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Disulfiram (Compound) upregulates MYC (Gene) and MYC (Gene) is downregulated by Bupropion (Compound) and Bupropion may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Disulfiram (Compound) upregulates CXCL8 (Gene) and CXCL8 (Gene) is bound by Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Disulfiram (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Tramadol (Compound) and Tramadol may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Disulfiram (Compound) downregulates NR2F6 (Gene) and NR2F6 (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Disulfiram (Compound) downregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a